Recently, Likang Life Sciences based in Beijing received approval from the Food and Drug Administration (FDA) of the United States for its Investigational New Drug (IND) application for LK101 Injection, a tumor neoantigen mRNA vaccine independently developed by the company. This marks the first tumor neoantigen mRNA vaccine product from China to gain the approval of FDA.

Compared with traditional treatment methods, the technology, with enhanced precision and safety, provides a new approach for the treatment of solid tumors. FDA's approval for this IND marks a significant breakthrough for China's biomedicine enterprises in the field of tumor immunotherapy.

(Sources: Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park)